CoChat

A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc)

Open access

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Impaired awareness of hypoglycaemia (IAH) is a major risk for severe hypoglycaemia in insulin treatment of type 1 diabetes (T1D). To explore the hypothesis that unhelpful health beliefs create barriers to regaining awareness, we conducted a multi-centre, randomised, parallel, two-arm trial (ClinicalTrials.gov NCT02940873) in adults with T1D and treatment-resistant IAH and severe hypoglycaemia, with blinded analysis of 12-month recall of severe hypoglycaemia at 12 and/or 24 months the primary outcome. Secondary outcomes included cognitive and emotional measures. Adults with T1D, IAH and severe hypoglycaemia despite structured education in insulin adjustment, +/− diabetes technologies, were randomised to the “Hypoglycaemia Awareness Restoration Programme despite optimised self-care” (HARPdoc, n = 49), a psychoeducation programme uniquely focussing on changing cognitive barriers to avoiding hypoglycaemia, or the evidence-based “Blood Glucose Awareness Training” (BGAT, n = 50), both delivered over six weeks. Median [IQR] severe hypoglycaemia at baseline was 5[2–12] per patient/year, 1[0–5] at 12 months and 0[0–2] at 24 months, with no superiority for HARPdoc (HARPdoc vs BGAT incident rate ratios [95% CI] 1.25[0.51, 3.09], p = 0.62 and 1.26[0.48, 3.35], p = 0.64 respectively), nor for changes in hypoglycaemia awareness scores or fear. Compared to BGAT, HARPdoc significantly reduced endorsement of unhelpful cognitions (Estimated Mean Difference for Attitudes to Awareness scores at 24 months, −2.07 [−3.37,−0.560], p = 0.01) and reduced scores for diabetes distress (−6.70[−12.50,−0.89], p = 0.02); depression (−1.86[−3.30, −0.43], p = 0.01) and anxiety (−1.89[−3.32, −0.47], p = 0.01). Despite positive impact on cognitive barriers around hypoglycaemia avoidance and on diabetes-related and general emotional distress scores, HARPdoc was not more effective than BGAT at reducing severe hypoglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-29488-x

Cites

52 of 53 references verified1 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CONSORT diagram for the HARPdoc RCT, showing participant flow through the study. Participant numbers at each stage are shown in the figure. * Patients judged as potential participants for the trial, including some (n = 329) identified through remote review of electronic patient records by researchers followed by “cold call” and others identified at clinical team meetings. ¥ Attendance of at least the first 3 days of allocated treatment (HARPdoc or BGAT) plus at least one 1:1 session for HARPdoc was considered as “received allocated treatment”.
Fig. 1 CONSORT diagram for the HARPdoc RCT, showing participant flow through the study. Participant numbers at each stage are shown in the figure. * Patients judged as potential participants for the trial, including some (n = 329) identified through remote review of electronic patient records by researchers followed by “cold call” and others identified at clinical team meetings. ¥ Attendance of at least the first 3 days of allocated treatment (HARPdoc or BGAT) plus at least one 1:1 session for HARPdoc was considered as “received allocated treatment”.CC BY · PubMed Central
Fig. 2 A box plot to present the summary statistics of the number of SH events in the previous 12 months (primary endpoint) by treatment arm and time point. The grey box represents the 25–75% interquartile range, the median is represented by the white line in each box and the whiskers cover the minimum to the maximum values, to the limit of 1.5× the IQR. Individual values for rates outside this limit have been excluded for clarity and are presented in Table 5. A three-level random intercept negative binomial model has been used, using a missing at random assumption (MAR) and a significance level of 2.5% (two sided). The N for each group is baseline: 49 and 50, 12 months 42 and 45 and 24 months 41 and 42 HARPdoc and BGAT respectively. Source data are available on request to SAA or IB, as described in the text.
Fig. 2 A box plot to present the summary statistics of the number of SH events in the previous 12 months (primary endpoint) by treatment arm and time point. The grey box represents the 25–75% interquartile range, the median is represented by the white line in each box and the whiskers cover the minimum to the maximum values, to the limit of 1.5× the IQR. Individual values for rates outside this limit have been excluded for clarity and are presented in Table 5. A three-level random intercept negative binomial model has been used, using a missing at random assumption (MAR) and a significance level of 2.5% (two sided). The N for each group is baseline: 49 and 50, 12 months 42 and 45 and 24 months 41 and 42 HARPdoc and BGAT respectively. Source data are available on request to SAA or IB, as described in the text.CC BY · PubMed Central
Fig. 3 Standardised effect sizes of secondary endpoints A2A, PAID and HADS. Values below zero indicate better outcomes in HARPdoc. The data are presented as estimated mean differences and 95% confidence intervals, with open triangles representing means of 12 month data; closed triangles representing means of 24-month data and bars representing 95% confidence intervals. Analysis is by a three-level random intercept linear regression regression model. A significance level of 5% (two sided) has been used. The standardised effect sizes for other secondary endpoints were not significant and are shown, together with numerical data for the depicted parameters, and the numbers providing data at each time point in each intervention, in Tables 4 and 6. Source data are available on request to S.A.A. or I.B., as described in the text.
Fig. 3 Standardised effect sizes of secondary endpoints A2A, PAID and HADS. Values below zero indicate better outcomes in HARPdoc. The data are presented as estimated mean differences and 95% confidence intervals, with open triangles representing means of 12 month data; closed triangles representing means of 24-month data and bars representing 95% confidence intervals. Analysis is by a three-level random intercept linear regression regression model. A significance level of 5% (two sided) has been used. The standardised effect sizes for other secondary endpoints were not significant and are shown, together with numerical data for the depicted parameters, and the numbers providing data at each time point in each intervention, in Tables 4 and 6. Source data are available on request to S.A.A. or I.B., as described in the text.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 61

Metadata

Authors
Amiel, S. A., Potts, L., Goldsmith, K., Jacob, P., Smith, E. L., Gonder-Frederick, L., Heller, S., Toschi, E., Brooks, A., Kariyawasam, D., Choudhary, P., Stadler, M., Rogers, H., Kendall, M., Sevdalis, N., Bakolis, I., & de Zoysa, N.
Affiliations
  • King's College London (GB)
  • King's College Hospital NHS Foundation Trust (GB)
  • University of Virginia (US)
  • University of Sheffield (GB)
  • Joslin Diabetes Center (US)
  • University Hospitals Dorset NHS Foundation Trust (GB)
  • Guy's Hospital (GB)
  • University of Leicester (GB)
Corresponding author
Amiel, Stephanie A.
Venue
Nature Communications
Published
2022-04-28
Volume
13
Issue
1
Pages
2229-2229
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4224994151
Cited by
61
References
51
Citations by year
2026: 9 · 2025: 11 · 2024: 19 · 2023: 11 · 2022: 11
FWCI
9.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, cc-by)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • Johns Hopkins University
  • South London and Maudsley NHS Foundation Trust
  • King's College Hospital NHS Foundation Trust
  • National Institute for Health and Care Research (CL-2012-17-002, CS-2017-17-023)
  • Department of Health and Social Care
  • King's College London
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK036836)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
Keywords
type 1 diabetes, severe hypoglycemia, psychoeducation, health beliefs, diabetes distress, depression, anxiety, diabetes self-management education, diabetes technology, insulin therapy, hypoglycemia prevention, cognitive behavioral therapy, fear of hypoglycemia
MeSH terms
Adult, Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemia, Insulin, Self Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc). https://app.cochat.ai/papers/10.1038/s41467-022-29488-x
The paper
Amiel, S. A., Potts, L., Goldsmith, K., Jacob, P., Smith, E. L., Gonder-Frederick, L., Heller, S., Toschi, E., Brooks, A., Kariyawasam, D., Choudhary, P., Stadler, M., Rogers, H., Kendall, M., Sevdalis, N., Bakolis, I., & de Zoysa, N. (2022). A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc). Nature Communications. https://doi.org/10.1038/s41467-022-29488-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.